Alkermes Highlights Strong 2025 Revenue, Alixorexton Breakthrough Therapy, and Strategic Avadel Acquisition
ALKS sits 18% above its 52-week low of $25.165.
Summary
Alkermes reported preliminary 2025 revenues over $1.45 billion, announced FDA Breakthrough Therapy for alixorexton, and confirmed its strategic acquisition of Avadel, signaling robust pipeline progress and market expansion.
Key Events · Product Development and Regulatory · ALKS
-
Preliminary 2025 Revenue Exceeds $1.45 Billion
Alkermes announced preliminary, unaudited total revenues for the year ended December 31, 2025, are estimated to be greater than $1.45 billion, indicating strong financial performance.
-
Alixorexton Receives FDA Breakthrough Therapy Designation
The company's lead orexin 2 receptor agonist, alixorexton, was granted FDA Breakthrough Therapy designation for narcolepsy type 1 (NT1), which is expected to accelerate its development and regulatory review.
-
Alixorexton to Enter Phase 3 in Q1 2026
Following positive topline data from its Vibrance phase 2 studies, Alkermes plans to initiate the registrational Phase 3 narcolepsy program for alixorexton in the first quarter of 2026.
-
Strategic Acquisition of Avadel Pharmaceuticals Nearing Close
The planned acquisition of Avadel Pharmaceuticals plc is expected to close in Q1 2026, which will augment Alkermes' revenue growth, enhance profitability, and accelerate its entry into the commercial sleep medicine market with LUMRYZ™.
Analysis · ALKS · Life Sciences
Alkermes plc provided a comprehensive update at the J.P. Morgan Healthcare Conference, revealing preliminary 2025 revenues exceeding $1.45 billion. The company highlighted significant progress in its neuroscience pipeline, particularly with alixorexton, which received FDA Breakthrough Therapy designation for narcolepsy type 1 and is set to enter Phase 3 in Q1 2026. Additionally, Alkermes detailed the strategic benefits of its planned acquisition of Avadel Pharmaceuticals, expected to close in Q1 2026, which will augment revenue growth, enhance profitability, and accelerate its entry into the commercial sleep medicine market with LUMRYZ™. These developments underscore Alkermes' strong growth trajectory and leadership in orexin innovation.
At the time of this filing, ALKS was trading at $29.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $25.17 to $36.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.